European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Aimmune Therapeutics (AIMT) PT Raised to $58 at RBC Capital
March 26, 2019 6:27 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $58.00 (from $55.00) while maintaining a Outperform rating.
ARTEMIS reads out positively in Europesetting the stage for a mid-19 MAA filing... MoreBaird Incrementally Positive on Aimmune Therapeutics (AIMT) ARTEMIS Topline Readout
March 25, 2019 12:52 PM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $64.00 price target on Aimmune Therapeutics (NASDAQ: AIMT) saying they are incrementally positive on ARTEMIS topline readout.
Skorney commented, "Aimmune announced today that the Phase 3 European trial of AR101 met its primary endpoint,... More
